Section 2: Selection, Procurement and Distribution
2SPD-020
IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY'S WORKLOAD: LESSONS LEARNED
2SPD-019
EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE
2SPD-018
BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT
2SPD-017
TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY
2SPD-016
COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
2SPD-015
INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS
2SPD-014
COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY
2SPD-013
INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES
2SPD-012
COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS
2SPD-011
COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE
2SPD-010
REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION
2SPD-009
AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS
2SPD-008
BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE
2SPD-007
USE OF DRUGS IN SPECIAL SITUATIONS
2SPD-006
ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES?
